中低危分化型甲状腺癌低剂量<sup>131</sup>I治疗后短期转归的临床分析

宋娟娟; 刘延晴; 林岩松

doi:10.19401/j.cnki.1007-3639.2019.03.008

您当前的位置：

首页 >

文章列表页 >

中低危分化型甲状腺癌低剂量¹³¹I治疗后短期转归的临床分析

论著 | 更新时间：2026-01-27

- 中低危分化型甲状腺癌低剂量¹³¹I治疗后短期转归的临床分析
- Clinical analysis of short-term outcome in low-to-intermediate-risk thyroid cancer after low-dose¹³¹I therapy
- 中国癌症杂志 2019年29卷第3期页码：207-211
- 作者机构：
  
  1. 中国医学科学院北京协和医学院北京协和医院核医学科,北京,100730
  2. 北京大学国际医院核医学科,北京,102206
- 作者简介：
- 基金信息：
  
  国家自然科学基金（81571714，81771875）。
- DOI：10.19401/j.cnki.1007-3639.2019.03.008
  中图分类号： R736.1
- 网络出版：2019-04-26，
  
  纸质出版：2019-04-26
- 稿件说明：
移动端阅览
宋娟娟，刘延晴，林岩松. 中低危分化型甲状腺癌低剂量

宋娟娟, 刘延晴, 林岩松. Clinical analysis of short-term outcome in low-to-intermediate-risk thyroid cancer after low-dose¹³¹I therapy[J]. China Oncology, 2019, 29(3): 207-211.
宋娟娟，刘延晴，林岩松. 中低危分化型甲状腺癌低剂量 DOI： 10.19401/j.cnki.1007-3639.2019.03.008.

宋娟娟, 刘延晴, 林岩松. Clinical analysis of short-term outcome in low-to-intermediate-risk thyroid cancer after low-dose¹³¹I therapy[J]. China Oncology, 2019, 29(3): 207-211. DOI： 10.19401/j.cnki.1007-3639.2019.03.008.

摘要

背景与目的：2015版美国甲状腺协会（American Thyroid Association，ATA）指南首次提出治疗反应评估体系（response-to-therapy assessment system，RTAS）。该研究根据此评估体系，探讨低剂量（1 110 MBq）

131

I在中低危分化型甲状腺癌（differentiated thyroid carcinoma，DTC）清甲治疗后短期内不同转归的影响因素。方法：回顾性分析2015年1月—2017年1月166例中低危DTC患者资料，男性50例，女性116例，平均年龄（39.61±10.23）岁。首次清甲剂量为1 110MBq，取得清甲前及清甲后6~12个月刺激性甲状腺球蛋白（stimulated thyroglobulin，sTg）及诊断性全身显像（diagnosticwhole body scan，Dx-WBS），根据结果分为最佳治疗反应（excellent response，ER）组与非最佳反应（non-excellent response，NER）组。采用两样本t检验、Mann-Whitney U秩和检验及χ

检验进行组间临床病理资料比较，采用Logistic回归分析影响清甲疗效的因素，采用受试者工作特征（receiver operating characteristic，ROC）曲线确定最佳界值。结果：ER组127例，NER组39例，ER率为76.5%（127/166）。治疗后短期随访ER组清甲治疗前sTg（preablative sTg，ps-Tg）明显低于NER组［1.5（0.04-30.57）ng/mL vs 17.6（0.04-21.52）ng/mL；U=2 479，P0.05］，且性别、年龄差异有统计学意义，男性及年龄稍小者更易出现NER。多因素分析显示，ps-Tg水平、肿瘤大小、淋巴结转移数目、性别、年龄及多灶性均为影响清甲疗效的相关因素（OR：0.361~2.875）。ROC曲线分析显示，ps-Tg最佳临界值为2.0 ng/mL。结论：ps-Tg水平较低、病灶较小、淋巴结转移数目较少、男性、年龄较小及单灶患者清甲治疗后短期内更易达到ER；且以ps-Tg值2.0 ng/mL为最佳临界点，对预测治疗后短期临床转归有较高的灵敏度和特异度。

Abstract

Background and purpose: The concept of response-to-therapy assessment system (RTAS) was first proposed in the 2015 American Thyroid Association (ATA) guidelines. This study aimed to investigate the different short-term outcomes of thyroid ablation with low-dose (1 110 MBq)

131

I for low-to-intermediate-risk thyroid cancer based on this system

and its probable influence factors. Methods: A total of 166 patients with differentiated thyroid carcinoma (DTC) ［50 males

116 females; average age: (39.61±10.23) years］ undergoing first thyroid ablation with 1 100 MBq

131

I from January 2015 to January 2017 were retrospectively observed. All patients underwent diagnostic whole body scan (Dx-WBS)

and the stimulated thyroglobulin (sTg) was measured before ablation and 6-12 months after ablation respectively. According to above results

patients were divided into excellent response (ER) group and non-excellent response (NER) group. Clinical and pathological characteristics of 2 groups were compared using two-sample t test

Mann-Whitney U test and χ

test. Logistic regression was used to identify the influence factors for efficacy of

131

I ablation

and the cut-off value was determined by receiver operating characteristic (ROC) curve analysis. Results: There were 127 patients in ER group and 39 patients in NER group. The successful ablation rate was 76.5% (127/166). Patients in ER group showed lower preablative sTg (ps-Tg) compared with patients in NER group. The ps-Tg levels were 1.5 (0.04-30.57) ng/mL and 17.6 (0.04- 21.52) ng/mL respectively (U=2 479

P0.05). Male and patient with younger age were more prevalent in NER group (P0.05). Logistic regression showed that ps-Tg

tumor size

the number of metastatic lymph nodes

gender

age and multifocality were independent predictors for efficacy of

131

I ablation (OR: 0.361-2.875). The optimal cut-off value of ps-Tg identified by ROC curve analysis was 2.0 ng/mL. Conclusion: The pati

ents with lower ps-Tg

smaller diameter of tumor

fewer lymph node metastases

male

younger age and single lesion are more likely to have ER within a short period following thyroid ablation. Ps-Tg of 2.0 ng/mL is identified as cut-off value for predicting the short-term therapeutic response

which has preferable sensitivity and specificity.

关键词

Keywords

references

查看原文

浏览量

2027

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

可疑甲状腺球蛋白增高性分化型甲状腺癌患者经¹³¹I治疗后的临床转归

诊断性¹³¹I全身显像在分化型甲状腺癌¹³¹I治疗决策中的作用

治疗前刺激性甲状腺球蛋白阴性合并淋巴结转移的分化型甲状腺癌¹³¹I治疗后的临床转归

分化型甲状腺癌被膜及被膜外微小侵犯与复发风险

《2025版美国甲状腺学会成人分化型甲状腺癌管理指南》解读：分化型甲状腺癌的外照射放疗进展

中低危分化型甲状腺癌低剂量131I治疗后短期转归的临床分析

Clinical analysis of short-term outcome in low-to-intermediate-risk thyroid cancer after low-dose131I therapy

DOI：10.19401/j.cnki.1007-3639.2019.03.008

摘要

Abstract

关键词

Keywords

references

中低危分化型甲状腺癌低剂量¹³¹I治疗后短期转归的临床分析

Clinical analysis of short-term outcome in low-to-intermediate-risk thyroid cancer after low-dose¹³¹I therapy